Researchers investigated methods for measuring prior exposure in patients with suspected, undocumented COVID-19 infection to give better access to care and counsel.
Researchers successfully detected evidence of prior SARS-CoV-2 infection in patients with post-viral syndrome (PVS) who had no documented positive test, according to a new study published in Neurology Neuroimmunology & Neuroinflammation.
Postacute sequelae of SARS-CoV-2 infection (PASC), also referred to as long COVID-19, is identified when physical, cognitive, or mental health symptoms last for an extended period following acute COVID-19 infection. Neurological symptoms often accompany PASC—deemed Neuro-PASC (NP)—such as headache, fatigue, cognitive impairment, autonomic disturbances, myalgia, among others.
It is reported that up to one-third of COVID-19 survivors develop PASC; however, these data cannot account for those with limited access to testing at the beginning of the pandemic or who were tested too late for SARS-CoV-2 detection. As a result, countless individuals who have developed PVS akin to PASC are unaware of their condition and are left without appropriate treatment or diagnosis.
A total of 29 patients with PVS associated with a suspected COVID-19 infection participated in assessments between June 2020 and April 2022 at Northwestern Medicine's Neuro COVID-19 clinic. Their cases were age- and sex-matched with 32 confirmed cases of NP (which had positive laboratory tests), and both groups were compared with a control of 18 nonexposed patients.
Thirty mL of blood were collected from the participants, and the amounts of antigen-specific antibody titers against the Spike receptor-binding domain (S-RBD) and the SARS-CoV-2 Nucleocapsid (N) protein were measured. At the time of their clinic visit, patients also completed a PROMIS quality of life measure to gauge their subjective perceptions of cognitive function, anxiety, depression, sleep disturbance, and fatigue. To objectively assess them for cognitive dysfunction (working memory, attention, processing speed, executive functioning), an NIH Toolbox was also given out.
Patients with PVS had a median age of 43, and most (93% each) were White and female, which did not differ significantly from the NP group. Six of the 29 patients with PVS were vaccinated. Their virus-specific immune responses were determined with a Spike or Nucleocapsid ELISA and an IFN-γ ELISPOT to measure antibody and T-cell production. Antibodies against S-RBD were detected in 2 of 23 unvaccinated patients with PVS, while 5 of 29 exhibited anti-Nucleocapsid antibodies. Researchers confirmed that the NP group had overall greater titers of both antibodies compared with the control and PVS groups.
Positive responses for T-cell activation occurred in 6 of 24 (25%) tested patients with PVS. The NP group demonstrated a similar response, but both of these groups showed increased levels of IFN-γ compared with the control group.
A SARS-CoV-2-specific immune response registered in 41% (12/29) patients with PVS—these individuals are now deemed PVS responders. These patients held many clinical similarities to their NP counterparts; however, they were appearing for clinical evaluations much later from the onset of their symptoms (10.7 vs 5.4 months; P = .0006).
Individuals with PVS and NP reported similar quality of life measures; their subjective perceptions of anxiety, depression, cognitive functioning, and fatigue were all lower compared to the normative population. Regarding objective cognitive measures, patients with PVS had higher scores for working memory but otherwise similar results for attention, processing speed, and executive functioning to patients with NP.
This study found that adaptive, specific immune responses to SARS-CoV-2 could be seen in a considerable amount of patients with PVS after a suspected COVID-19 infection. The clinical presentation and immune responses in patients with PVS carried many similarities to patients with NP who had previous, laboratory-confirmed COVID-19 exposure.
The researchers mention the importance of anti-Nucleocapsid antibody testing for the future of patient care. Previous data have revealed the promise of measuring for N-specific T-cell and antibody responses to determine SARS-CoV-2 infection associated with PVS. Additionally, because a large population of US individuals have already received Spike COVID-19 vaccinations, focusing on anti–N antibody response is imperative for detecting prior exposure for patients without a documented positive test.
In their concluding thoughts, the authors discuss how COVID-19 and these obstacles in accessing certain health care have revealed a noteworthy disparity in populations reeling from undiagnosed SARS-CoV-2 infection. Although their small sample size largely consisted of White females, individuals sharing their experiences represent an underserved population because most post-COVID-19 clinics in the US require proof of exposure before administering any treatment. Considering their findings, future screenings for patients with PVS should implement an evaluation of anti–Nucleocapsid antibody responses to guide the course of patient treatment.
“Patients with PVS may benefit from the same clinical care as confirmed patients with NP, and the absence of a positive SARS-CoV-2 test should not preclude or delay treatment.”
Reference
Orban ZS, Visvabharathy L, Giraldo GSP, Jumenez M, Koralnik IJ. SARS-CoV-2-specific immune responses in patients with postviral syndrome after suspected COVID-19. Neurol Neuroimmunol Neuroinflamm. Published online August 23, 2023. doi:10.1212/NXI.0000000000200159
Joanne Mizell: Lifestyle Modification Programs Take Holistic Aim at Metabolic Disease
May 1st 2024Joanne Mizell shares insurer strategies in addressing the escalating rates of metabolic diseases, highlighting the importance of holistic treatment methods like lifestyle modification programs, which integrate nutrition, physical activity, and community engagement.
Read More
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
BRCA-Like Classification May Be a Useful Biomarker for Olaparib Response in Ovarian Cancer
May 1st 2024Adding olaparib to maintenance therapy with bevacizumab was associated with significantly longer survival for patients with ovarian cancer whose tumors have a BRCA-like genomic profile, but not among those with non-BRCA-like tumors, a study found.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Diving Deep Into Specialty Pharmacy: Insights and Forecasts From IQVIA’s Doug Long
May 1st 2024Doug Long, MBA, vice president of industry relations at IQVIA, covered a bevy of stakeholder investment–related topics in his presentation at AXS24 on trends in specialty pharmacy, chief among them challenges facing the industry, obesity medications, generics and biosimilars, new product launches, and the outlook for the US market.
Read More